Lipoteichoic acid from staphylococcus epidermidis and its use to modulate neuronal activity via pd-1 inhibitory signalling in neurons
OwnerPraveen Thumbikatinventor
Life of this patent
Estimating the term…
Abstract
Disclosed herein are compositions comprising lipoteichoic acid (LTA) and the use thereof for modulating neuronal activity. The disclosed LTA compositions may be prepared using LTA that is derived from the Gram positive bacteria Staphylococcus epidermidis. The disclosed LTA compositions may be administered to treat pain, including but not limited to chronic pelvic pain syndrome (CPPS), neurogenic pain, or neurogenic inflammation via PD-1 inhibitory signaling in neurons. The disclosed LTA compositions may be administered in order to modulate the expression of endogenous opioids.
Claims20
A method for treating pain in a subject in need thereof, the method comprising administering to the subject a composition comprising an effective amount of Staphylococcus epidermidis lipoteichoic acid (SELTA) for modulating the activity of the PD-1 pathway.
A method of treating neurogenic pain in a subject in need thereof, the method comprising:
- administering a pharmaceutical composition comprising Staphylococcus epidermidis lipoteichoic acid (SELTA) to the subject to treat neurogenic pain in the subject.
A method of treating neurogenic inflammation in a subject in need thereof, the method comprising administering a pharmaceutical composition comprising Staphylococcus epidermidis lipoteichoic acid (SELTA) to the subject to treat neurogenic inflammation in the subject.
Dependencies are inferred from the claim text.